References
  1. Giovannuci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.
  2. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011; 29: 40–6.
  3. Tan BX, Yao WX, Ge J, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 117(22): 5103–5111.
  4. S.C. Larsson, A. Wolk, Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 2011;54(5), 1013–1018.
  5. Feng X, Wang G, Li N, et al. The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population‐based prospective study. Br J Cancer 2017; 117: 1405.
  6. Fall K, Garmo H, Gudbjornsdottir S, et al. Diabetes mellitus and prostate cancer risk: a nationwide case‐control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev 2013; 22: 1102–09.
  7. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta‐analysis. Diabetologia 2004; 47: 1071–78.
  8. Kasper J, Giovannucci E. A meta‐analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056
  9. Lawrence YR, Morag O, Benderly M, et al. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013; 16: 181–186.
  10. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005; 161: 147–152.
  11. Tseng CH. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care. 2011; 34: 616–621.
  12. Li Q, Kuriyama S, Kakizaki M, et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki CohortStudy. Cancer Causes Control. 2010; 21: 1025-32
  13. Peehl DM, Stamey TA. Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol. 1986; 22(2):82-90.
  14. Wright JL, Plymate SR, Porter MP, et al. Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):204-8.
  15. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001; 44(2):129-46.
  16. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab. 2007; 9(3):233–245
  17. Monnier VM, Sell DR, Nagaraj RH, et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes. 1992; 41 Suppl 2():36-41.
  18. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008; 93(4):1143-52.
  19. Li T, Qin W, Liu Y, et al. Effect of RAGE  gene polymorphisms and circulating sRAGE levels on susceptibility to gastric cancer: a case-control study. Cancer Cell Int. 2017
  20. Nankali M, Karimi J, Goodarzi M, et al. TIncreased Expression of the Receptor for Advanced Glycation End-Products (RAGE) Is Associated with Advanced Breast Cancer Stage. Oncol Res Treat. 2016; 39:622-628
  21. Nguyen AH, Detty SQ, Agrawal DK. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review. Anticancer Res. 2017; 37(1):1-7
  22. Kang R, Tang D, Schapiro NE, et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene. 2014; 33:567–577.
  23. Yang S, Pinney SM, Mallick P, et al. Impact of Oxidative Stress Biomarkers and Carboxymethyllysine (an AdvancedGlycation End Product) on Prostate Cancer: A Prospective Study. Clin Genitourin Cancer. 2015; 13(5):347-51
  24. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol (2016) 40(2):244–249
  25. Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163: 1632–1642.
  26. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299:27609.
  27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). EJC 2009; 45:228–47.
  28. Xu XC, Abuduhadeer X, Zhang WB, et al (2013). Knockdown of RAGE inhibits growth and invasion of gastric cancer Cells. Eur J Histochem , 29, 240-6.
  29. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. The Prostate. 2005; 64:92–100.
  30. Cai H, Xu Z, Xu T, et al. Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res Rev. 2015; 31(4):336-43
  31. Chen M, Luo Y, Yang S, et al. Association of diabetes mellitus with prostate cancer grade and prostate-specific antigen in Chinese biopsy population.  Diabetes research and clinical practice  141 (2018): 80-87.
  32. Tsilidis KK, Allen NE, Appleby PN, et al. Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2015;136(2):372-81
  33. Xu H, Jiang HW, Ding GX, et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Clin Res Pract 2013; 99(3):241-9
  34. Moreira DM, Anderson T, Gerber L, et al. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control. 2011; 22:977–983
  35. Fukushima H, Masuda H, Kawakami S, et al. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL. Urology. 2012; 79:1329–1334.
  36. Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Int J Impot Res. 2003; 15(Suppl 4): S14–S20.
  37. Peskoe SB, Joshu CE, Rohrmann S, et al. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate. 2015; 75:1167–1176.
  38. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1992; 117:807–811.
  39. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Jama. 2003; 289:76–79.
  40. Drinda S, Franke S, Ruster M, et al. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int. 2005; 25:411–413.
  41. Hu P, Lai D, Lu P, Gao J, He H. ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int J Mol Med. 2012; 29:613–618.
  42. Yuan X, Zhang Z, Gong K, Zhao P, Qin J, Liu N. Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats. Biol Pharm Bull. 2011; 34:618–623.
  43. Zhang J, Shao S, Han D, et al. High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway. Int J Oncol. 2018; 53(2):659-671
  44. Zhao C, Bao J, Lu Y, et al. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res. American journal of cancer research  4.4 (2014): 369.
  45. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005; 103:1092–1095.
  46. McGinley KF, McMahon GC, Brown GA.  Impact of the US Preventive Services Task Force Grade D recommendation: assessment of evaluations for elevated prostate-specific antigen and prostate biopsies in a large urology group practice following statement revision.  Rev Urol . 2015; 17(3):171-177.
  47. Staquicini FI, Cardó-Vila M, Kolonin MG, et al. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011; 108(46):18637–42.
  48. Tateno T, Ueno S, Hiwatashi K, et al. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2009; 16(2):440-6
  49. Fahmueller YN, Nagel D, Hoffmann RT, et al. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 2013; 132(10):2349-58
TABLE 1 Demographic, biochemical, histopathological parameters and RAGE score of all three groups and subgroups (BPH-LPCa-MetPCa)